Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T19:40:47.326Z Has data issue: false hasContentIssue false
  • English
  • Français

Incentive salience: novel treatment strategies for major depression

Published online by Cambridge University Press:  01 August 2013

David P. Soskin ,
Daphne J. Holt ,
Garret R. Sacco  and
Maurizio Fava
David P. Soskin*
Affiliation:
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
Daphne J. Holt
Affiliation:
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
Garret R. Sacco
Affiliation:
Department of Psychology, University of Delaware, Newark, Delaware, USA
Maurizio Fava
Affiliation:
Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA
*
*Address for correspondence: Dr. D. Soskin, Center for Treatment-Resistant Depression, Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, Boston, MA 02114, USA. (Email dsoskin@partners.org)
Get access Rights & Permissions [Opens in a new window]

Abstract

This article proposes that a recent shift in our understanding of dopamine function may support translational research to target deficits in positive emotions and reward processing in individuals with major depressive disorder (MDD). We review how dopamine functions to modulate approach behaviors in response to positive incentives, and we describe the incentive salience hypothesis, which posits that dopamine primarily modulates “wanting,” or anticipatory reward, rather than “liking,” or subjective pleasure. Although the incentive salience hypothesis was first proposed to help explain how drugs of abuse may reinforce harmful behaviors in the absence of continued pleasure or “liking,” it may also provide a basis for understanding and developing new treatment approaches for MDD. Specifically, it provides a rationale for combining behaviorally activating psychotherapies and pro-dopaminergic agents to target impaired reward processing in MDD.

Keywords

Behavioral activation therapycognitive behavioral therapydopamineincentive salience hypothesismajor depressive disordernovel treatment strategiespsychopharmacologywell-being therapy
Type
Review Articles
Information
CNS Spectrums , Volume 18 , Issue 6 , December 2013 , pp. 307 - 314
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Healy, D. The Antidepressant Era. Cambridge, MA: Harvard University Press; 1997: 317.Google Scholar
2. History of Twentieth Century Medicine Group, Wellcome Trust, Wellcome Trust. Medicine, Society, and History Division. Wellcome witnesses to twentieth century medicine, 1997. http://eprints.ucl.ac.uk/2078/1/wit2.pdfGoogle Scholar
3.Shorter, E, Tyrer, P. Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease. BMJ. 2003; 327(7407): 158–160.CrossRefGoogle ScholarPubMed
4.Papakostas, GI, Fava, M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009; 19(1): 34–40.CrossRefGoogle ScholarPubMed
5.Gelenberg, AJ, Thase, ME, Meyer, RE, etal. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008; 69(10): 1513–1528.CrossRefGoogle Scholar
6.Fava, M, Davidson, KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996; 19(2): 179–200.CrossRefGoogle ScholarPubMed
7.Ramana, R, Paykel, ES, Cooper, Z, etal. Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med. 1995; 25(6): 1161–1170.CrossRefGoogle ScholarPubMed
8.Rush, AJ, Trivedi, MH, Wisniewski, SR, etal. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11): 1905–1917.CrossRefGoogle ScholarPubMed
9.Thase, ME, Nierenberg, AA, Vrijland, P, etal. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010; 25(4): 189–198.CrossRefGoogle ScholarPubMed
10.Rasmussen, N. America's first amphetamine epidemic 1929–1971: a quantitative and qualitative retrospective with implications for the present. Am J Public Health. 2008; 98(6): 974–985.CrossRefGoogle ScholarPubMed
11.Taneja, I, Haman, K, Shelton, RC, Robertson, D. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol. 2007; 27(1): 76–79.CrossRefGoogle ScholarPubMed
12.Depue, RA, Iacono, WG. Neurobehavioral aspects of affective disorders. Annu Rev Psychol. 1989; 40: 457–492.CrossRefGoogle ScholarPubMed
13.Depue, RA, Collins, PF. Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci. 1999; 22(3): 491–517; discussion 518–569.CrossRefGoogle ScholarPubMed
14.Blood, AJ, Zatorre, RJ. Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. Proc Natl Acad Sci U S A. 2001; 98(20): 11818–11823.CrossRefGoogle ScholarPubMed
15.Kunig, G, Leenders, KL, Martin-Solch, C, etal. Reduced reward processing in the brains of parkinsonian patients. Neuroreport. 2000; 11(17): 3681–3687.CrossRefGoogle ScholarPubMed
16.Martin-Solch, C, Magyar, S, Kunig, G, etal. Changes in brain activation associated with reward processing in smokers and nonsmokers: a positron emission tomography study. Exp Brain Res. 2001; 139(3): 278–286.CrossRefGoogle ScholarPubMed
17.Drevets, WC, Gautier, C, Price, JC, etal. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001; 49(2): 81–96.CrossRefGoogle ScholarPubMed
18.Roy, A, Agren, H, Pickar, D, etal. Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am J Psychiatry. 1986; 143(12): 1539–1545.Google ScholarPubMed
19.Lambert, G, Johansson, M, Agren, H, Friberg, P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry. 2000; 57(8): 787–793.CrossRefGoogle ScholarPubMed
20.Agren, H, Reibring, L. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry. 1994; 27(1): 2–6.CrossRefGoogle ScholarPubMed
21.Klimek, V, Schenck, JE, Han, H, Stockmeier, CA, Ordway, GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002; 52(7): 740–748.CrossRefGoogle ScholarPubMed
22.Di Mascio, M, Di Giovanni, G, Di Matteo, V, Prisco, S, Esposito, E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull. 1998; 46(6): 547–554.CrossRefGoogle ScholarPubMed
23.Meyer, JH, McNeely, HE, Sagrati, S, etal. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006; 163(9): 1594–1602.CrossRefGoogle ScholarPubMed
24.Parsey, RV, Oquendo, MA, Zea-Ponce, Y, etal. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001; 50(5): 313–322.CrossRefGoogle ScholarPubMed
25.Hirvonen, J, Karlsson, H, Kajander, J, etal. Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl). 2008; 197(4): 581–590.CrossRefGoogle ScholarPubMed
26.Krishnan, V, Nestler, EJ. The molecular neurobiology of depression. Nature. 2008; 455(7215): 894–902.CrossRefGoogle ScholarPubMed
27.Nestler, EJ, Carlezon, WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006; 59(12): 1151–1159.CrossRefGoogle ScholarPubMed
28.Roybal, K, Theobold, D, Graham, A, etal. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A. 2007; 104(15): 6406–6411.CrossRefGoogle ScholarPubMed
29.Nelson, JC. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000; 61(Suppl 2): 13–19.Google ScholarPubMed
30.Fava, M, Thase, ME, DeBattista, C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005; 66(1): 85–93.CrossRefGoogle ScholarPubMed
31.Ravindran, AV, Kennedy, SH, O'Donovan, MC, etal. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008; 69(1): 87–94.CrossRefGoogle ScholarPubMed
32.Candy, M, Jones, L, Williams, R, Tookman, A, King, M. Psychostimulants for depression. Cochrane Database Syst Rev. 2008; (2): CD006722.Google ScholarPubMed
33.Pecina, S, Smith, KS, Berridge, KC. Hedonic hot spots in the brain. Neuroscientist. 2006; 12(6): 500–511.CrossRefGoogle ScholarPubMed
34.Salamone, JD, Correa, M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012; 76(3): 470–485.CrossRefGoogle ScholarPubMed
35.McClure, SM, Daw, ND, Montague, PR. A computational substrate for incentive salience. Trends Neurosci. 2003; 26(8): 423–428.CrossRefGoogle ScholarPubMed
36.Kelley, AE, Delfs, JM. Dopamine and conditioned reinforcement: I. differential effects of amphetamine microinjections into striatal subregions. Psychopharmacology (Berl). 1991; 103(2): 187–196.CrossRefGoogle ScholarPubMed
37.Wyvell, CL, Berridge, KC. Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward “wanting” without enhanced “liking” or response reinforcement. J Neurosci. 2000; 20(21): 8122–8130.CrossRefGoogle ScholarPubMed
38.Berridge, KC, Robinson, TE, Aldridge, JW. Dissecting components of reward: ‘liking’, ‘wanting’, and learning. Curr Opin Pharmacol. 2009; 9(1): 65–73.CrossRefGoogle ScholarPubMed
39.Knutson, B, Bjork, JM, Fong, GW, etal. Amphetamine modulates human incentive processing. Neuron. 2004; 43(2): 261–269.CrossRefGoogle ScholarPubMed
40.Wise, R. The dopamine synapse and the notion of ‘pleasure centers’ in the brain. Trends Neurosci. 1980; 3: 91–95.CrossRefGoogle Scholar
41.Berridge, KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl). 2007; 191(3): 391–431.CrossRefGoogle ScholarPubMed
42.Pecina, S, Cagniard, B, Berridge, KC, Aldridge, JW, Zhuang, X. Hyperdopaminergic mutant mice have higher “wanting” but not “liking” for sweet rewards. J Neurosci. 2003; 23(28): 9395–9402.CrossRefGoogle Scholar
43.Salamone, JD, Correa, M, Mingote, SM, Weber, SM. Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol. 2005; 5(1): 34–41.CrossRefGoogle ScholarPubMed
44.Berridge, KC, Robinson, TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998; 28(3): 309–369.CrossRefGoogle ScholarPubMed
45.Pecina, S, Berridge, KC. Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness? J Neurosci. 2005; 25(50): 11777–11786.CrossRefGoogle ScholarPubMed
46.Smith, KS, Berridge, KC. Opioid limbic circuit for reward: Interaction between hedonic hotspots of nucleus accumbens and ventral pallidum. J Neurosci. 2007; 27(7): 1594–1605.CrossRefGoogle ScholarPubMed
47.Volkow, ND, Wang, GJ, Fowler, JS, etal. “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse. 2002; 44(3): 175–180.CrossRefGoogle ScholarPubMed
48.Knutson, B, Westdorp, A, Kaiser, E, Hommer, D. FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage. 2000; 12(1): 20–27.CrossRefGoogle ScholarPubMed
49.Haber, SN, Knutson, B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010; 35(1): 4–26.CrossRefGoogle ScholarPubMed
50.Jacobson, N, Martell, CR, Dimidjian, S. Behavioral activation treatment for depression: returning to contextual roots. Clinical Psychology: Science and Practice. 2001; 8: 255–270.Google Scholar
51.Vieth, AZ, Strauman, TJ, Kolden, GG, etal. Self-system therapy (SST): a theory-based psychotherapy for depression. Clinical Psychology: Science and Practice. 2003; 10: 245–268.Google Scholar
52.Fava, GA, Rafanelli, C, Cazzaro, M, Conti, S, Grandi, S. Well-being therapy: a novel psychotherapeutic approach for residual symptoms of affective disorders. Psychol Med. 1998; 28(2): 475–480.CrossRefGoogle ScholarPubMed
53.Carl, JR, Soskin, DP, Kerns, C, Barlow, DH. Positive emotion regulation in emotional disorders: a theoretical review. Clin Psychol Rev. 2013; 33(3): 343–360.CrossRefGoogle ScholarPubMed
54.Ressler, KJ, Rothbaum, BO, Tannenbaum, L, etal. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004; 61(11): 1136–1144.CrossRefGoogle ScholarPubMed